Zoetis (ZTS) announced that Health Canada has approved Lenivia for the alleviation of pain associated with osteoarthritis in dogs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Buy Rating on Zoetis: Strategic Initiatives and Long-term Growth Potential Amid Short-term Challenges
- Zoetis’s Strategic Launch of Innovative Monoclonal Antibodies for Osteoarthritic Pain Management
- Zoetis receives positive opinion from CVMP for Lenivia
- Zoetis Declares Q4 2025 Dividend of $0.50
- Zoetis receives conditional approval for Dectomax-CA1 injectable